Cited by 887Antiplatelet Therapy and Cardiovascular DiseasesCoronary Interventions and DiagnosticsAcute Myocardial Infarction Research

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting

Open access

Collet, Jean-Philippe, Cuisset, Thomas, Rangé, Grégoire, Cayla, Guillaume, Elhadad, Simon, Pouillot, Christophe, Henry, Patrick, Motreff, Pascal, Carrié, Didier, Boueri, Ziad, Belle, Loic, Van Belle, Eric, Rousseau, Hélène, Aubry, Pierre, Monségu, Jacques, Sabouret, Pierre, O'Connor, Stephen A., Abtan, Jérémie, Kerneis, Mathieu, Saint-Etienne, Christophe, Barthélémy, Olivier, Beygui, Farzin, Silvain, Johanne, Vicaut, Eric, Montalescot, Gilles·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1209979

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Patients' responses to oral antiplatelet therapy are subject to variation. Bedside monitoring offers the opportunity to improve outcomes after coronary stenting by individualizing therapy. METHODS: We randomly assigned 2440 patients scheduled for coronary stenting at 38 centers to a strategy of platelet-function monitoring, with drug adjustment in patients who had a poor response to antiplatelet therapy, or to a conventional strategy without monitoring and drug adjustment. The primary end point was the composite of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization 1 year after stent implantation. For patients in the monitoring group, the VerifyNow P2Y12 and aspirin point-of-care assays were used in the catheterization laboratory before stent implantation and in the outpatient clinic 2 to 4 weeks later. RESULTS: In the monitoring group, high platelet reactivity in patients taking clopidogrel (34.5% of patients) or aspirin (7.6%) led to the administration of an additional bolus of clopidogrel, prasugrel, or aspirin along with glycoprotein IIb/IIIa inhibitors during the procedure. The primary end point occurred in 34.6% of the patients in the monitoring group, as compared with 31.1% of those in the conventional-treatment group (hazard ratio, 1.13; 95% confidence interval [CI], 0.98 to 1.29; P=0.10). The main secondary end point, stent thrombosis or any urgent revascularization, occurred in 4.9% of the patients in the monitoring group and 4.6% of those in the conventional-treatment group (hazard ratio, 1.06; 95% CI, 0.74 to 1.52; P=0.77). The rate of major bleeding events did not differ significantly between groups. CONCLUSIONS: This study showed no significant improvements in clinical outcomes with platelet-function monitoring and treatment adjustment for coronary stenting, as compared with standard antiplatelet therapy without monitoring. (Funded by Allies in Cardiovascular Trials Initiatives and Organized Networks and others; ARCTIC ClinicalTrials.gov number, NCT00827411.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1209979

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citation
Guidelines on myocardial revascularization
Wijns, W. C., Kolh, P. H., Danchin, N., Mario, C. D., Falk, V., Folliguet, T. A., Garg, S., Huber, K., James, S. K., Knuuti, J., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq277 · Cited by 3,228
Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention
Price, M. J. (2011) · JAMA · doi:10.1001/jama.2011.290 · Cited by 1,311
Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention
Lincoff, A. M., Bittl, J. A., Harrington, R. A., Feit, F., Kleiman, N. S., Jackman, J. D., Sarembock, I. J., Cohen, D. J., Spriggs, D. J., Ebrahimi, R., et al. (2003) · JAMA · doi:10.1001/jama.289.7.853 · Cited by 1,158
Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate
Bonello, L., Tantry, U. S., Marcucci, R., Blindt, R., Angiolillo, D. J., Becker, R. C., Bhatt, D. L., Cattaneo, M., Collet, J., Cuisset, T., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.04.047 · Cited by 1,151
Self-citation
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization
Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205512 · Cited by 874
Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation
Breet, N. J., van Werkum, J. W., Bouman, H. J., Kelder, J. C., Ruven, H. J. T., Bal, E. T., Deneer, V. H. M., Harmsze, A. M., der Heyden, J. A. S. V., Rensing, B. J. W. M., et al. (2010) · JAMA · doi:10.1001/jama.2010.181 · Cited by 850
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial
Mehta, S. R., Tanguay, J., Eikelboom, J. W., Jolly, S. S., Joyner, C. D., Granger, C. B., Faxon, D. P., Rupprecht, H., Budaj, A., Avezum, Á., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61088-4 · Cited by 812
Self-citation
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Tricoci, P., Huang, Z., Held, C., Moliterno, D. J., Armstrong, P. W., de Werf, F. V., White, H. D., Aylward, P. E., Wallentin, L. C., Chen, E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109719 · Cited by 756
Self-citation

Show all 26 references

Sorted by citations

Items 401–500 of 883

Gender and Outcomes following Guided De-Escalation of Antiplatelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Gender Substudy
Groß, L., Kupka, D., Trenk, D., Geisler, T., Hadamitzky, M., Löw, A., Orban, M., Huber, K., Kiss, R. G., Merkely, B. P., et al. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1692441 · Cited by 11
Epidemiology and secondary prevention of ischemic stroke in patients on antiplatelet drug: a retrospective cohort study
Gallo, A., Galliazzo, S., Grazioli, S., Guasti, L., Ageno, W., & Squizzato, A. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01893-y · Cited by 11
The role of perioperative antiplatelet therapy and platelet reactivity testing in carotid revascularization: overview of the evidence.
Leunissen, T. C., de Borst, G. J., Janssen, P. W. A., & ten Berg, J. M. (2015) · PubMed · Cited by 11
Point-of-care Measurements of Platelet Inhibition After Clopidogrel Loading in Patients With Acute Coronary Syndrome: Comparison of Generic and Branded Clopidogrel Bisulfate
Seo, K., Tahk, S., Yang, H., Yoon, M., Shin, J., Choi, S., Lim, H., Hwang, G., Choi, B., Park, J., et al. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.07.018 · Cited by 11
A new mechanism of action of thienopyridine antiplatelet drugs – A role for gastric nitrosthiol metabolism?
Anderson, R. A., Bundhoo, S. S., & James, P. E. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.08.045 · Cited by 11
The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial
Liang, Z., Li, Y., Wang, J., Wang, D., Wang, S., Ma, L., Liu, H., Yang, L., Stone, G. W., & Han, Y. (2016) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26407 · Cited by 11
Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks
Singh, M., Bhatt, D. L., Stone, G. W., Rihal, C. S., Gersh, B. J., Lennon, R. J., Narula, J., & Fuster, V. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.06.013 · Cited by 11
Implementing a pharmacogenetic-driven algorithm to guide dual antiplatelet therapy (DAPT) in Caribbean Hispanics: protocol for a non-randomised clinical trial
Hernández-Suárez, D. F., Melín, K., Marín‐Maldonado, F., Nuñez-Medina, H., Gonzalez, A. F., González‐Sepúlveda, L., Rivas‐Tumanyan, S., Naik, H., Ruaño, G., Scott, S. A., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-038936 · Cited by 11
Large early variation of residual platelet reactivity in Acute Coronary Syndrome patients treated with clopidogrel
Alfredsson, J., Lindahl, T. L., Gustafsson, K. M., Janzon, M., Jonasson, L., Logander, E., Nilsson, L. E., & Swahn, E. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.05.021 · Cited by 11
Tratamiento antiagregante plaquetario personalizado
Gurbel, P. A., Rafeedheen, R., & Tantry, U. S. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.01.013 · Cited by 10
Changes in platelet maturity and reactivity following acute ST-segment elevation myocardial infarction
Pedersen, O. B., Nissen, P. H., Pasalic, L., Hvas, A., Kristensen, S. D., & Grove, E. L. (2024) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2024.102652 · Cited by 10
CYP2C19 Genotype‐Guided Antiplatelet Therapy and Clinical Outcomes in Patients Undergoing a Neurointerventional Procedure
Tunehag, K. R., Pearce, A. F., Fox, L. P., Stouffer, G. A., Solander, S. Y., & Lee, C. R. (2025) · Clinical and Translational Science · doi:10.1111/cts.70131 · Cited by 10
A high ratio of ADP–TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone
Olivier, C. B., Schnabel, K., Brandt, C., Weik, P., Olschewski, M., Zhou, Q., Bode, C., Diehl, P., & Moser, M. (2014) · Clinical Research in Cardiology · doi:10.1007/s00392-014-0737-8 · Cited by 10
Relationship between high platelet reactivity on clopidogrel and long-term clinical outcomes after drug-eluting stents implantation (PAINT-DES): a prospective, propensity score-matched cohort study
Gao, X., Lu, S., Ge, Z., Zuo, G., Wang, Z., Wang, F., Kong, X., Chai, D., Chen, S., & Zhang, J. (2018) · BMC Cardiovascular Disorders · doi:10.1186/s12872-018-0841-1 · Cited by 10
Antiplatelet Drugs in the Management of Thrombotic/Ischemic Events in Children
Michelson, A. D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813456-6.00060-6 · Cited by 10
Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndrome
Cuisset, T., Cayla, G., Quilici, J., Pankert, M., Deharo, P., Bonnet, G., Grosdidier, C., Beguin, S., Morange, P., Bonnet, J., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.04.052 · Cited by 10
Self-citation
High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy
Leé, S., Vargová, K., Hizoh, I., Horváth, Z., Gulácsi-Bárdos, P., Sztupinszki, Z. M., Apró, A., Kovács, A., Préda, I., Tóth-Zsámboki, E., et al. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.11.029 · Cited by 10
Genetic testing and antiplatelet treatment: Still way to go?
Oikonomou, E. K., Παπαγεωργίου, Ν., Papaioannou, S., Toutouzas, K. P., Latsios, G., Siasos, G., & Tousoulis, D. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.03.281 · Cited by 10
Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome
Kukuła, K., Kłopotowski, M. M., Kunicki, P. K., Jamiołkowski, J., Dębski, A., Bekta, P., Polańska-Skrzypczyk, M., Chmielak, Z., & Witkowski, A. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0433-x · Cited by 10
Antiplatelet agents in uncertain clinical scenarios—a bleeding nightmare
Esmonde, S., Sharma, D., & Peace, A. J. (2018) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2018.06.09 · Cited by 10
The Efficacy of P2Y12 Reactive Unit to Predict the Periprocedural Thromboembolic and Hemorrhagic Complications According to Clopidogrel Responsiveness and Safety of Modification of Dual Antiplatelet Therapy : A Meta-Analysis
Kim, H. J., Oh, J. S., Park, S. Q., Yoon, S.-M., Ahn, H. S., & Kim, B. (2019) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2019.0082 · Cited by 10
Antithrombotic therapy and revascularisation strategies in people with diabetes and coronary artery disease
Rocca, B., Rubboli, A., & Zaccardi, F. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319880045 · Cited by 11
Ticagrelor
Samoš, M., Fedor, M., Kovář, F., Duraj, L., Stančiaková, L., Galajda, P., Staško, J., Kubisz, P., & Mokáň, M. (2015) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000406 · Cited by 10
P2Y12Platelet Receptors: Importance in Percutaneous Coronary Intervention
Falcão, F. J. D. A., Carvalho, L. D. P., Chan, M. Y., Alves, C. M. R., Carvalho, A. C. C., & Caixeta, A. M. (2013) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20130162 · Cited by 10
Does the response to aspirin and clopidogrel vary over 6 months in patients with ischemic heart disease?
Khanna, V., Mikael, R., Thayalasamy, K., Sambu, N., Dimitrov, B. D., Englyst, N. A., Calver, A., Corbett, S. J., Gray, H., Simpson, I. A., et al. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12909 · Cited by 10
New antiplatelet agents for cardiovascular disease
Chua, D., & Nishi, C. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.130033 · Cited by 11
Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y12 receptor inhibitors
Rollini, F., Franchi, F., Singh, K., Cho, J. R., Bhatti, M., DeGroat, C., Hu, J., Aggarwal, N. R., Alobaidi, Z., Thano, E., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-05-0377 · Cited by 10
Individual long-term variation of platelet reactivity in patients with dual antiplatelet therapy after myocardial infarction
Alfredsson, J., Swahn, E., Gustafsson, K. M., Janzon, M., Jonasson, L., Logander, E., Nilsson, L. E., & Lindahl, T. L. (2018) · Platelets · doi:10.1080/09537104.2018.1479519 · Cited by 10
Pharmacogenomic Testing to Select Antiplatelet Therapy
Price, M. J., & Angiolillo, D. J. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.021 · Cited by 10
Actualización en cardiología intervencionista 2013
Hernández, F., Cuevas, J. R. R., del Blanco, B. G., & Trillo, R. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.10.028 · Cited by 9
Pharmacodynamic and Clinical Implications of Switching Between P2Y12 Receptor Antagonists
Bagai, A., Chua, D., Cohen, E. A., Saw, J., Verma, S., Vijayaraghavan, R., Welsh, R. C., & FITCHETT, D. H. (2014) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000030 · Cited by 9
Comparison of Antiplatelet Efficacy and Tolerability of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients After Percutaneous Coronary Intervention: A Prospective, Multicenter, Randomized, Open-Label, Phase IV, Noninferiority Trial
Park, J., Koo, B., Choi, W., Kim, S. Y., Park, J., Kwan, J., Park, C. G., & Kim, H.-S. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.12.004 · Cited by 9
Clinical Background and Coronary Artery Lesions Characteristics in Japanese Patients With Acute Coronary Syndrome Suffering Major Bleeding
Kobayashi, N., Shibata, Y., Kurihara, O., Todoroki, T., Tsutsumi, M., Shirakabe, A., Shigihara, S., Sawatani, T., Kiuchi, K., Takano, M., et al. (2024) · Circulation Reports · doi:10.1253/circrep.cr-24-0003 · Cited by 9
Universal versus platelet reactivity assay-driven use of P2Y12 inhibitors in acute coronary syndrome patients
Limone, B. L., & Coleman, C. I. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-07-0557 · Cited by 9
Combined Antiplatelet Therapy: Still a Sweeping Combination in Cardiology
Manolis, A. S., Manolis, T. A., Papadimitriou, P., Koulouris, S., & Melita, H. (2013) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/1871525711311020009 · Cited by 9
Point-of-care assessment of platelet reactivity in the emergency department may facilitate rapid rule-out of acute coronary syndromes: a prospective cohort pilot feasibility study
Darling, C. E., Mercado, J. A. S., Quiroga-Castro, W., Tecco, G. F., Zelaya, F., Conci, E., Sala, J., Smith, C. S., Michelson, A. D., Whittaker, P., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-003883 · Cited by 9
Correlation Between SNPs in Candidate Genes and VerifyNow-Detected Platelet Responsiveness to Aspirin and Clopidogrel Treatment
Cui, H., Lin, S., Chen, X., Gao, W., Li, X., Zhou, H., Du, W., Wang, S., & Zhao, R. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6585-6 · Cited by 9
Impact of Point-of-Care Platelet Function Testing Among Patients With and Without Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study)
Rinaldi, M. J., Gohs, F. X., Kirtane, A. J., Brodie, B. R., Stuckey, T., Redfors, B., McAndrew, T., Witzenbichler, B., Weisz, G., Neumann, F., et al. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.11.026 · Cited by 9
Antiplatelet Therapy Monitoring in Neonates and Children
Huang, J. Y., Soeharto, D. A., Damara, I., Ignjatović, V., Linden, M. D., & Monagle, P. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1676375 · Cited by 9
Assessment of platelet function utilizing viscoelastic testing
Racine‐Brzostek, S., & Asmis, L. M. (2020) · Transfusion · doi:10.1111/trf.16081 · Cited by 9
Prevalence and significance of CYP 2 C 19*2 and CYP 2 C 19*17 alleles in a N ew Z ealand acute coronary syndrome population
Larsen, P., Johnston, L. R., Holley, A., Flamme, A. C. L., Smyth, L. C. D., Chua, E. W., Kennedy, M. A., & Harding, S. A. (2015) · Internal Medicine Journal · doi:10.1111/imj.12698 · Cited by 9
Platelet Function Testing in Patients with Acute Coronary Syndrome
Orban, M., & Sibbing, D. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9450-7 · Cited by 9
Comparison of On-Treatment Platelet Reactivity Between Triple Antiplatelet Therapy With Cilostazol and Standard Dual Antiplatelet Therapy in Patients Undergoing Coronary Interventions
Panchal, H. B., Shah, T., Patel, P., Albalbissi, K., Molnár, J., Coffey, B., Khosla, S., & Ramu, V. K. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413495971 · Cited by 9
Individualised dual antiplatelet therapy in a patient with short bowel syndrome after acute myocardial infarction with coronary artery stenting
Droppa, M., Karathanos, A., Gawaz, M., & Geisler, T. (2015) · BMJ Case Reports · doi:10.1136/bcr-2014-205227 · Cited by 9
Type 2 Diabetes and ADP Receptor Blocker Therapy
Samoš, M., Fedor, M., Kovář, F., Mokáň, M., Bolek, T., Galajda, P., Kubisz, P., & Mokáň, M. (2015) · Journal of Diabetes Research · doi:10.1155/2016/6760710 · Cited by 9
Effect of Modifying Antiplatelet Treatment to Ticagrelor in High-Risk Coronary Patients With Low Response to Clopidogrel (MATTIS)
Musallam, A., Orvin, K., Perl, L., Mosseri, M., Arbel, Y., Roguin, A., & Lev, E. I. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.11.023 · Cited by 9
Clinical and Educational Impact of Pharmacogenomics Testing: A Case Series From the INGENIOUS Trial
Pierson, R. C., Gufford, B. T., Desta, Z., & Eadon, M. T. (2017) · Pharmacogenomics · doi:10.2217/pgs-2017-0042 · Cited by 9
Association Between Residual Platelet Reactivity on Clopidogrel Treatment and Severity of Coronary Atherosclerosis: Intrinsic Hypercoagulability as a Mediator
Zhao, X., Wu, H., Xu, H., Shen, L., Fan, B., & Ge, J. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01032-2 · Cited by 9
Antiplatelet Therapy and Platelet Activity Testing for Neurointerventional Procedures
Fukuda, K. A., Beaman, C. B., & Szeder, V. (2024) · Stroke Vascular and Interventional Neurology · doi:10.1161/svin.124.001376 · Cited by 8
Relevance of High Bleeding Risk and Postdischarge Bleeding in Patients Undergoing Percutaneous Coronary Intervention
Ingraham, B. S., Valgimigli, M., Angiolillo, D. J., Capodanno, D., Rao, S. V., Urban, P. M., & Singh, M. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.09.010 · Cited by 8
Platelets and inflammation—insights from platelet non-coding RNA content and release in the Bruneck study and the PACMAN-AMI trial
Gutmann, C., Barwari, T., Schulte, C., Theofilatos, K., Singh, B., Takov, K., Suna, G., Chan, M. V., Armstrong, P. C. J., Cassel, C., et al. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf100 · Cited by 8
Update on Interventional Cardiology 2013
Hernández, F., Cuevas, J. R. R., del Blanco, B. G., & Trillo, R. (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.10.026 · Cited by 8
New Antiplatelet Agents and the Role of Platelet Function Testing in Acute Coronary Syndromes
Sinhal, A. R., & Aylward, P. E. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.07.429 · Cited by 8
Prise en charge du risque hémorragique associé aux agents antiplaquettaires
Martin, A., Houssany-Pissot, S., Zlotnik, D., Taylor, G., & Godiér, A. (2017) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2017.01.013 · Cited by 8
Navigating the Course of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Review of Guided Approaches
Ammirabile, N., Landolina, D., & Capodanno, D. (2023) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.123.013450 · Cited by 8
Factor XI and Atrial Fibrillation: A Mismatched Pairing?
Rocca, B., & Cate, H. T. (2025) · European Cardiology Review · doi:10.15420/ecr.2024.61 · Cited by 8
Viewpoint: Mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes
DiNicolantonio, J. J., & Serebruany, V. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-02-0142 · Cited by 8
Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction
Lee, J. H., Ahn, S. G., Lee, J., Youn, Y. J., Ahn, M., Kim, J., Yoo, B., Lee, S., Yoon, J., Kim, J., et al. (2015) · Platelets · doi:10.3109/09537104.2015.1095875 · Cited by 8
Monitoring platelet function: what have we learned from randomized clinical trials?
Deharo, P., & Cuisset, T. (2018) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2018.10.10 · Cited by 8
Self-citation
Predictors and Management of Antiplatelet-Related Bleeding Complications for Acute Coronary Syndrome in Chinese Elderly Patients
Wan, J., Wang, P., Zhou, P., Liu, S., Wang, D., Kan, J., Hou, J., Zuo, L., Ma, S., & Yang, Y. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000494543 · Cited by 8
Antithrombotic therapy in high-risk patients after percutaneous coronary intervention; study design, cohort profile and incidence of adverse events
Olie, R. H., van der Meijden, P. E. J., Vries, M. J. A., Veenstra, L. F., Hof, A. W. J. V. ’., ten Berg, J. M., Henskens, Y., & Cate, H. T. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01606-2 · Cited by 8
Differential Impact of Cytochrome 2C19 Allelic Variants on Three Different Platelet Function Tests in Clopidogrel-Treated Patients
Olie, R. H., Hensgens, R. R. K., Wijnen, P. A. H. M., Veenstra, L. F., de Greef, B. T. A., Vries, M. J. A., van der Meijden, P. E. J., ten Berg, J. M., Cate, H. T., Bekers, O., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173992 · Cited by 8
Platelet Reactivity and Cardiovascular Mortality Risk in the LURIC Study
Berger, M., Dressel, A., Kleber, M. E., März, W., Hellstern, P., Marx, N., & Schütt, K. S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051913 · Cited by 8
Monitoring of Antiplatelet Therapy
Davidson, S. J. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3175-1_25 · Cited by 8
Randomized, Double-Blind, Active Comparator Pharmacodynamic Study of Platelet Inhibition with Crushed and Integral Formulations of Clopidogrel and Ticagrelor in Acute Coronary Syndrome
Perla, H. T., Thomson, V. S., Attumalil, T. V., Geevar, T., Alex, A. G., Dave, R. G., Nair, S. C., Gowri, S. M., Mony, P. K., George, P. V., et al. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00591-8 · Cited by 8
Oral Antiplatelet Therapy in Acute Coronary Syndromes: Recent Developments
Zeymer, U. (2013) · Cardiology and Therapy · doi:10.1007/s40119-013-0011-6 · Cited by 8
Clopidogrel: A multifaceted affair
Martínez‐Quintana, E., & Tugores, A. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.413 · Cited by 8
CYP2C19*2 genotype influence in acute coronary syndrome patients undergoing serial clopidogrel dose tailoring based on platelet function testing: Analysis from randomized controlled trial NCT02096419
Samardžić, J., Božina, N., Škorić, B., Ganoci, L., Petričević, M., Krpan, M., Pašalić, M., & Miličić, D. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.03.171 · Cited by 8
The Ratio of ADP- to TRAP-Induced Platelet Aggregation Quantifies P2Y12-Dependent Platelet Inhibition Independently of the Platelet Count
Olivier, C. B., Meyer, M., Bauer, H., Schnabel, K., Weik, P., Zhou, Q., Bode, C., Moser, M., & Diehl, P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149053 · Cited by 8
Contribution of whole platelet aggregometry to the endovascular management of unruptured aneurysms: an institutional experience
Aoun, S. G., Welch, B. G., Pride, L., White, J. A., Novakovic, R., Hoes, K. S., & Sarode, R. (2016) · Journal of NeuroInterventional Surgery · doi:10.1136/neurintsurg-2016-012623 · Cited by 8
Association of CYP2C19*2 Polymorphism with Clopidogrel Response and 1-year Major Adverse Cardiovascular Events in A Multiethnic Population with Drug-Eluting Stents
Tan, S. S. N., Fong, A. Y. Y., Mejin, M., Gerunsin, J., Kong, K. L., Chin, F. Y. Y., Tiong, L. L., Lim, M. S. H., Said, A., Khiew, N. Z., et al. (2017) · Pharmacogenomics · doi:10.2217/pgs-2017-0078 · Cited by 8
Platelet-Derived Thrombogenicity Measured by Total Thrombus-Formation Analysis System in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Kikuchi, S., Tsukahara, K., Ichikawa, S., Abe, T., Minamimoto, Y., Kimura, Y., Akiyama, E., Nakayama, N., Okada, K., Matsuzawa, Y., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-19-1043 · Cited by 8
Comparison of dual antiplatelet therapy prescribed as one-pill versus two-pill regimen
Lim, W., Chae, I., Yoon, C., Choi, D., Lim, S., Park, W., Doh, J., Kim, S., Kim, M., Lee, S., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-12-0931 · Cited by 8
Platelet reactivity influences clot structure as assessed by fractal analysis of viscoelastic properties
Knowles, R., Lawrence, M. J., Ferreira, P., Hayman, M. A., D׳Silva, L., Stanford, S., Sabra, A., Tucker, A. T., Hawkins, K. M., Williams, P. R., et al. (2017) · Platelets · doi:10.1080/09537104.2017.1306039 · Cited by 8
Vasodilator-stimulated phosphoprotein-guided Clopidogrel maintenance therapy reduces cardiovascular events in atrial fibrillation patients requiring anticoagulation therapy and scheduled for percutaneous coronary intervention: a prospective cohort study
Hu, C., Zhang, X., Liu, Y., Gao, Y., Zhao, X., Zhou, H., Liu, Y., Liu, Y., & Wang, X. (2018) · BMC Cardiovascular Disorders · doi:10.1186/s12872-018-0853-x · Cited by 8
Towards Personalized Antithrombotic Treatments: Focus on P2Y12 Inhibitors and Direct Oral Anticoagulants
Terrier, J. E., Daali, Y., Fontana, P., Csajka, C., & Reny, J. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00792-y · Cited by 8
Optimal Aspirin Dose in Acute Coronary Syndromes: an Emerging Consensus
DiNicolantonio, J. J., Norgard, N. B., Meier, P., Lavie, C. J., O’Keefe, J. H., Niazi, A. K., Chatterjee, S., Packard, K. A., D’Ascenzo, F., Cerrato, E., et al. (2014) · Future Cardiology · doi:10.2217/fca.14.7 · Cited by 8
Diabetes Mellitus and Clopidogrel Response Variability∗
Price, M. J. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.07.003 · Cited by 8
More transparency for a therapeutic window in platelet P2Y12inhibition?
Storey, R. F. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv137 · Cited by 8
Antiplatelet drugs and platelet reactivity: is it time to halt clinical research on tailored strategies?
Reny, J., & Fontana, P. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.993608 · Cited by 8
Aspirin Treatment and Outcomes in Patients Undergoing Percutaneous Coronary Intervention
Angiolillo, D. J., & Cho, J. R. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.06.1157 · Cited by 8
Endogenous fibrinolysis in STEMI: important before and after primary PCI
Sinnaeve, P., & de Werf, F. V. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy760 · Cited by 8
Most Recent Evidence Behind Aggregometry and Genotyping Methods as Platelet Function Testing for Tailored Anti-Platelet Treatment Among PCI Patients
Gajda, S., Kołtowski, Ł., & Tomaniak, M. (2015) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/27922 · Cited by 7
Precision antiplatelet therapy
Rocca, B., & Patrono, C. (2023) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2023.100138 · Cited by 7
Dual antiplatelet treatment after stenting: is longer better?
Sibbing, D., & Maßberg, S. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60768-6 · Cited by 7
High platelet reactivity – the challenge of prolonged anticoagulation therapy after ACSI
Brouwer, M. A., Verheugt, F. W. A., & Focks, J. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-08-0582 · Cited by 7
2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons Endorsed by the American Association for Clinical Chemistry WRITING COMMITTEE MEMBERS*
Amsterdam, E. A., WENGER, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H. M., Kelly, R. F., Kontos, M. C., et al. (2014) · Cited by 7
Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel
Olivier, C. B., Schnabel, K., Weber, S., Zhou, Q., Bode, C., Moser, M., & Diehl, P. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1340-9 · Cited by 7
Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response
Xu, L., Hu, X., Zhang, S., Li, J., Zhu, H., Xu, K., Chen, J., & Li, C. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.179786 · Cited by 7
Antiplatelet strategies in elderly people: still a long way to go
Sibbing, D., & Maßberg, S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31387-3 · Cited by 7
Genetic and Molecular Testing in Thrombosis and Hemostasis: Informing Surveillance, Treatment, and Prognosis
Crispin, P. J., & Koo, R. M. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1677020 · Cited by 7
Monitoring of Antiplatelet Therapy
Tantry, U. S., Myat, A., & Gurbel, P. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-47462-5_45 · Cited by 7
P2Y12 Antagonists in Cardiovascular Disease—Finding the Best Balance Between Preventing Ischemic Events and Causing Bleeding
Fernando, H., McFadyen, J. D., Wang, X., Shaw, J. A., Stub, D. A., & Peter, K. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.854813 · Cited by 7
Successes and future objectives in acute coronary syndrome
de Werf, F. V. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.129 · Cited by 7
Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor
Davis, E. M., Knezevich, J. T., & Teply, R. M. (2013) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s41859 · Cited by 7
Positive clinical response to clopidogrel is independent of paraoxonase 1 Q192R and CYP2C19 genetic variants
Martínez‐Quintana, E., Medina-Gil, J. M., Rodríguez‐González, F., Garay‐Sánchez, P., Limiñana, J. M., Saavedra, P., & Tugores, A. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.275 · Cited by 7
Intrinsic platelet reactivity before start with clopidogrel as predictor for on-clopidogrel platelet function and long-term clinical outcome
Valina, C. M., Bömicke, T., Amann, M., Stratz, C., Nührenberg, T. G., Trenk, D., Neumann, F., & Hochholzer, W. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-10-0900 · Cited by 7
Oral P2Y12Receptor Inhibitors in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions: Current Knowledge and Future Directions
Jain, N., & Reilly, R. F. (2016) · Seminars in Dialysis · doi:10.1111/sdi.12484 · Cited by 7
Prognostic Role of Platelet Reactivity in Patients With Acute Coronary Syndromes
Cavallari, I., Nusca, A., Ricottini, E., & Sciascio, G. D. (2014) · Cardiology in Review · doi:10.1097/crd.0000000000000034 · Cited by 7
Point of care platelet function testing in routine neurointerventional care is unjustified
Chandra, R. V. (2013) · Journal of NeuroInterventional Surgery · doi:10.1136/neurintsurg-2013-010808 · Cited by 7

Authors: Collet, J.-P., Cuisset, T., Rangé, G., Cayla, G., Elhadad, S., Pouillot, C., Henry, P., Motreff, P., Carrié, D., Boueri, Z., Belle, L., Van Belle, E., Rousseau, H., Aubry, P., Monségu, J., Sabouret, P., O'Connor, S. A., Abtan, J., Kerneis, M., Saint-Etienne, C., Barthélémy, O., Beygui, F., Silvain, J., Vicaut, E., & Montalescot, G.
Affiliations: Pitié-Salpêtrière Hospital (FR)
Hôpital de la Timone (FR)
Les Hôpitaux de Chartres (FR)
Centre Hospitalier Universitaire de Nîmes (FR)
Hôpital Lariboisière (FR)
Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
Hôpital Rangueil (FR)
Hôpital Bichat-Claude-Bernard (FR)
HIA du Val-de-Grâce à Paris (FR)
ORCID: Collet, Jean-Philippe
Cuisset, Thomas
Rangé, Grégoire
Cayla, Guillaume
Elhadad, Simon
Pouillot, Christophe
Henry, Patrick
Motreff, Pascal
Carrié, Didier
Rousseau, Hélène
Aubry, Pierre
Sabouret, Pierre
Abtan, Jérémie
Barthélémy, Olivier
Beygui, Farzin
Silvain, Johanne
Montalescot, Gilles
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-11-29
Volume: 367
Issue: 22
Pages: 2100-2109
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1209979
OpenAlex: W2145323902
Cited by: 887
References: 26
Citations by year: 2026: 15 · 2025: 20 · 2024: 22 · 2023: 31 · 2022: 31 · 2021: 47 · 2020: 44 · 2019: 52 · 2018: 72 · 2017: 77 · 2016: 80 · 2015: 123 · 2014: 122 · 2013: 141 · 2012: 8
FWCI: 81.10
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords: antiplatelet therapy, coronary stenting, platelet function monitoring, VerifyNow P2Y12 assay, clopidogrel, prasugrel, aspirin, stent thrombosis, bleeding events, glycoprotein IIb/IIIa inhibitors, individualized dosing, major adverse cardiovascular events
MeSH terms: Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Coronary Disease, Coronary Thrombosis, Female, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Platelet Aggregation Inhibitors, Pyridines, Thiophenes, Ticlopidine, Stents, Drug Monitoring, Point-of-Care Systems, Retreatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks